New Platform Detects MicroRNA Directly in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Oct 2015 |
|
Biotech and other life science researchers will benefit from the introduction of a novel microRNA (miRNA) detection platform.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Electrolyte Analyzer
BKE-B
New
HPV Test
Allplex HPV28 Detection
Latest BioResearch News
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read more
Molecular Diagnostics
view channel
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Earlier prognostic information could improve triage and guide treatment... Read more
Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more
Immunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more
Microbiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more
Industry
view channel
FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
Endocrine therapy resistance remains a significant challenge in estrogen receptor–positive, human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer, where tumor evolution can limit... Read more
